Defense World
13 Dec 2025, 08:58 UTC · 40w ago
Verdict
Headline leans bearish. We score BCRX −0.30 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.30moderately bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Alkeon Capital Management reduced its position in BioCryst Pharmaceuticals (BCRX) by 20.8% during the most recent reporting quarter.
More negative than 77% of claims this week
Alkeon Capital Management continues to hold 5,714,021 shares of BioCryst Pharmaceuticals following the sale of 1.5 million shares.
Continue reading
5 related stories
More negative than 68% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 44% of claims this week
Which stocks this story touches
More negative than 68% of ticker scores this week
A major institutional investor reduced its stake in the company by over 20%.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+13.5%
Price is moving against the score
$8.59 vs $7.57 close before publication (Dec 12) · not market-adjusted
BCRX chart →
